FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209315604> ?p ?o ?g. }

• W3209315604 endingPage "e274" @default.
• W3209315604 startingPage "e273" @default.
• W3209315604 abstract "Purpose/Objective(s)There is a lack of early predictive measures of outcome for patients with intermediate-risk prostate cancer (PCa) treated with stereotactic body radiotherapy (SBRT). We aim to explore 4-year PSA response rate (4yPSARR) as an early predictive measure.Materials/MethodsIndividual patient data from 6 institutions for patients with intermediate-risk PCa treated with SBRT between 2006 and 2016 with a 4-year (42-54 months) PSA available were analyzed. Cumulative incidences of biochemical failure and metastasis were calculated using Nelson-Aalen estimates and overall survival was calculated using the Kaplan-Meier method. Biochemical failure-free survival was analyzed according to 4yPSARR with groups dichotomized based on PSA < 0.4 ng/mL or ≥ 0.4 ng/mL and compared using the log-rank test. Multivariable competing risk analysis was performed to predict for biochemical failure and development of metastasis.ResultsSix-hundred thirty-seven patients were included, including 424 (67%) with favorable and 213 (33%) with unfavorable intermediate-risk disease. Median follow-up was 6.2 years (IQR 4.9-7.9). The cumulative incidence of biochemical failure and metastasis, and overall survival at 6 years was 7%, 0.6% and 97%, respectively. The cumulative incidence of biochemical failure at 6 years if 4yPSARR < 0.4ng/mL was 1.7%, compared to 27% if 4yPSARR ≥ 0.4 ng/mL (P < 0.0001). On multivariable competing risk analysis, 4yPSARR was a statistically significant predictor of biochemical failure-free survival (sHR 15.3, 95% CI 7.5-31.3, P < 0.001) and metastasis-free survival (sHR 31.2, 95% CI 3.1-311.6, P = 0.003).Conclusion4yPSARR is an encouraging early predictor of outcome in patients with intermediate-risk PCa treated with SBRT. Validation in prospective trials is warranted. There is a lack of early predictive measures of outcome for patients with intermediate-risk prostate cancer (PCa) treated with stereotactic body radiotherapy (SBRT). We aim to explore 4-year PSA response rate (4yPSARR) as an early predictive measure. Individual patient data from 6 institutions for patients with intermediate-risk PCa treated with SBRT between 2006 and 2016 with a 4-year (42-54 months) PSA available were analyzed. Cumulative incidences of biochemical failure and metastasis were calculated using Nelson-Aalen estimates and overall survival was calculated using the Kaplan-Meier method. Biochemical failure-free survival was analyzed according to 4yPSARR with groups dichotomized based on PSA < 0.4 ng/mL or ≥ 0.4 ng/mL and compared using the log-rank test. Multivariable competing risk analysis was performed to predict for biochemical failure and development of metastasis. Six-hundred thirty-seven patients were included, including 424 (67%) with favorable and 213 (33%) with unfavorable intermediate-risk disease. Median follow-up was 6.2 years (IQR 4.9-7.9). The cumulative incidence of biochemical failure and metastasis, and overall survival at 6 years was 7%, 0.6% and 97%, respectively. The cumulative incidence of biochemical failure at 6 years if 4yPSARR < 0.4ng/mL was 1.7%, compared to 27% if 4yPSARR ≥ 0.4 ng/mL (P < 0.0001). On multivariable competing risk analysis, 4yPSARR was a statistically significant predictor of biochemical failure-free survival (sHR 15.3, 95% CI 7.5-31.3, P < 0.001) and metastasis-free survival (sHR 31.2, 95% CI 3.1-311.6, P = 0.003). 4yPSARR is an encouraging early predictor of outcome in patients with intermediate-risk PCa treated with SBRT. Validation in prospective trials is warranted." @default.
• W3209315604 created "2021-11-08" @default.
• W3209315604 creator A5003931641 @default.
• W3209315604 creator A5011765788 @default.
• W3209315604 creator A5020292379 @default.
• W3209315604 creator A5026731460 @default.
• W3209315604 creator A5041615709 @default.
• W3209315604 creator A5046826646 @default.
• W3209315604 creator A5056302482 @default.
• W3209315604 creator A5067339881 @default.
• W3209315604 creator A5075740763 @default.
• W3209315604 creator A5082915859 @default.
• W3209315604 date "2021-11-01" @default.
• W3209315604 modified "2023-09-27" @default.
• W3209315604 title "4-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated With Ablative Therapies: The Sprat Analysis" @default.
• W3209315604 doi "https://doi.org/10.1016/j.ijrobp.2021.07.886" @default.
• W3209315604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701066" @default.
• W3209315604 hasPublicationYear "2021" @default.
• W3209315604 type Work @default.
• W3209315604 sameAs 3209315604 @default.
• W3209315604 citedByCount "0" @default.
• W3209315604 crossrefType "journal-article" @default.
• W3209315604 hasAuthorship W3209315604A5003931641 @default.
• W3209315604 hasAuthorship W3209315604A5011765788 @default.
• W3209315604 hasAuthorship W3209315604A5020292379 @default.
• W3209315604 hasAuthorship W3209315604A5026731460 @default.
• W3209315604 hasAuthorship W3209315604A5041615709 @default.
• W3209315604 hasAuthorship W3209315604A5046826646 @default.
• W3209315604 hasAuthorship W3209315604A5056302482 @default.
• W3209315604 hasAuthorship W3209315604A5067339881 @default.
• W3209315604 hasAuthorship W3209315604A5075740763 @default.
• W3209315604 hasAuthorship W3209315604A5082915859 @default.
• W3209315604 hasBestOaLocation W32093156041 @default.
• W3209315604 hasConcept C10515644 @default.
• W3209315604 hasConcept C120665830 @default.
• W3209315604 hasConcept C121332964 @default.
• W3209315604 hasConcept C121608353 @default.
• W3209315604 hasConcept C126322002 @default.
• W3209315604 hasConcept C126894567 @default.
• W3209315604 hasConcept C143998085 @default.
• W3209315604 hasConcept C2779013556 @default.
• W3209315604 hasConcept C2780192828 @default.
• W3209315604 hasConcept C50382708 @default.
• W3209315604 hasConcept C509974204 @default.
• W3209315604 hasConcept C61511704 @default.
• W3209315604 hasConcept C66339696 @default.
• W3209315604 hasConcept C71924100 @default.
• W3209315604 hasConcept C72563966 @default.
• W3209315604 hasConcept C88879693 @default.
• W3209315604 hasConceptScore W3209315604C10515644 @default.
• W3209315604 hasConceptScore W3209315604C120665830 @default.
• W3209315604 hasConceptScore W3209315604C121332964 @default.
• W3209315604 hasConceptScore W3209315604C121608353 @default.
• W3209315604 hasConceptScore W3209315604C126322002 @default.
• W3209315604 hasConceptScore W3209315604C126894567 @default.
• W3209315604 hasConceptScore W3209315604C143998085 @default.
• W3209315604 hasConceptScore W3209315604C2779013556 @default.
• W3209315604 hasConceptScore W3209315604C2780192828 @default.
• W3209315604 hasConceptScore W3209315604C50382708 @default.
• W3209315604 hasConceptScore W3209315604C509974204 @default.
• W3209315604 hasConceptScore W3209315604C61511704 @default.
• W3209315604 hasConceptScore W3209315604C66339696 @default.
• W3209315604 hasConceptScore W3209315604C71924100 @default.
• W3209315604 hasConceptScore W3209315604C72563966 @default.
• W3209315604 hasConceptScore W3209315604C88879693 @default.
• W3209315604 hasIssue "3" @default.
• W3209315604 hasLocation W32093156041 @default.
• W3209315604 hasLocation W32093156042 @default.
• W3209315604 hasOpenAccess W3209315604 @default.
• W3209315604 hasPrimaryLocation W32093156041 @default.
• W3209315604 hasRelatedWork W1514396125 @default.
• W3209315604 hasRelatedWork W2160911489 @default.
• W3209315604 hasRelatedWork W2591601502 @default.
• W3209315604 hasRelatedWork W3034129954 @default.
• W3209315604 hasRelatedWork W4200194158 @default.
• W3209315604 hasRelatedWork W4200585213 @default.
• W3209315604 hasRelatedWork W4226367882 @default.
• W3209315604 hasRelatedWork W4246070242 @default.
• W3209315604 hasRelatedWork W4250577720 @default.
• W3209315604 hasRelatedWork W4252476369 @default.
• W3209315604 hasVolume "111" @default.
• W3209315604 isParatext "false" @default.
• W3209315604 isRetracted "false" @default.
• W3209315604 magId "3209315604" @default.
• W3209315604 workType "article" @default.